Filing Details
- Accession Number:
- 0000904454-21-000834
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-15 13:24:53
- Reporting Period:
- 2021-12-15
- Accepted Time:
- 2021-12-15 13:24:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1590560 | Uniqure N.v. | QURE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1696698 | Iii Edward Alexander Kuta | C/O Uniqure N.v. Paasheuvelweg 25A Amsterdam P7 11058BP | Executive Vp, Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2021-12-15 | 6,000 | $5.31 | 72,642 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2021-12-15 | 6,000 | $27.90 | 66,642 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2021-12-15 | 6,000 | $0.00 | 6,000 | $5.31 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 44,000 | 2027-01-23 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
- The Stock Option vested 25% on January 23, 2018 (the first anniversary of the date of grant), and vests 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
Billionaire Hedge Funds
